Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
Immunomodulator Therapy in Inflammatory Bowel Disease.

Current treatment options in gastroenterology

Legnani PE, Kornbluth A.
PMID: 11469977
Curr Treat Options Gastroenterol. 2001 Jun;4(3):199-205. doi: 10.1007/s11938-001-0032-4.

6-Mercaptopurine and its prodrug counterpart, azathioprine, have proven efficacy in the induction and maintenance of remission, fistula closure, and steroid sparing in patients with Crohn's disease. Long-term follow-up has demonstrated the safety of the purine analogues, with no increased...

Cite
Legnani PE, Kornbluth A. Immunomodulator Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2001;4(3):199-205doi: 10.1007/s11938-001-0032-4.
Legnani, P. E., & Kornbluth, A. (2001). Immunomodulator Therapy in Inflammatory Bowel Disease. Current treatment options in gastroenterology, 4(3), 199-205. https://doi.org/10.1007/s11938-001-0032-4
Legnani, Peter E., and Kornbluth, Asher. "Immunomodulator Therapy in Inflammatory Bowel Disease." Current treatment options in gastroenterology vol. 4,3 (2001): 199-205. doi: https://doi.org/10.1007/s11938-001-0032-4
Legnani PE, Kornbluth A. Immunomodulator Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2001 Jun;4(3):199-205. doi: 10.1007/s11938-001-0032-4. PMID: 11469977.
Copy Download .nbib Format: NLM
Small-Signal Performance and Modeling of sub-50nm nMOSFETs with f above 460-GHz.

Solid-state electronics

Dimitrov V, Heng J, Timp K, Dimauro O, Chan R, Hafez M, Feng J, Sorsch T, Mansfield W, Miner J, Kornblit A, Klemens F, Bower J, Cirelli R, Ferry EJ, Taylor A, Feng M, Timp G.
PMID: 20706596
Solid State Electron. 2008 Jun 01;52(6):899-908. doi: 10.1016/j.sse.2008.01.025.

We have fabricated and tested the performance of sub-50nm gate nMOSFETs to assess their suitability for mixed signal applications in the super high frequency (SHF) band, i.e. 3-30GHz. For a 30nm×40 μm×2 device, we found f(T) =465GHz at V(ds)=2V,...

Cite
Dimitrov V, Heng J, Timp K, et al. Small-Signal Performance and Modeling of sub-50nm nMOSFETs with f above 460-GHz. Solid State Electron. 2008;52(6):899-908doi: 10.1016/j.sse.2008.01.025.
Dimitrov, V., Heng, J., Timp, K., Dimauro, O., Chan, R., Hafez, M., Feng, J., Sorsch, T., Mansfield, W., Miner, J., Kornblit, A., Klemens, F., Bower, J., Cirelli, R., Ferry, E. J., Taylor, A., Feng, M., & Timp, G. (2008). Small-Signal Performance and Modeling of sub-50nm nMOSFETs with f above 460-GHz. Solid-state electronics, 52(6), 899-908. https://doi.org/10.1016/j.sse.2008.01.025
Dimitrov, V, et al. "Small-Signal Performance and Modeling of sub-50nm nMOSFETs with f above 460-GHz." Solid-state electronics vol. 52,6 (2008): 899-908. doi: https://doi.org/10.1016/j.sse.2008.01.025
Dimitrov V, Heng J, Timp K, Dimauro O, Chan R, Hafez M, Feng J, Sorsch T, Mansfield W, Miner J, Kornblit A, Klemens F, Bower J, Cirelli R, Ferry EJ, Taylor A, Feng M, Timp G. Small-Signal Performance and Modeling of sub-50nm nMOSFETs with f above 460-GHz. Solid State Electron. 2008 Jun 01;52(6):899-908. doi: 10.1016/j.sse.2008.01.025. PMID: 20706596; PMCID: PMC2919744.
Copy Download .nbib Format: NLM
Adalimumab: Another Treatment Option for Moderate-to-Severe UC.

Gastroenterology & hepatology

Kornbluth AA.
PMID: 23943670
Gastroenterol Hepatol (N Y). 2013 May;9(5):321.

No abstract available.

Cite
Kornbluth AA. Adalimumab: Another Treatment Option for Moderate-to-Severe UC. Gastroenterol Hepatol (N Y). 2013;9(5):321
Kornbluth, A. A. (2013). Adalimumab: Another Treatment Option for Moderate-to-Severe UC. Gastroenterology & hepatology, 9(5), 321.
Kornbluth, Asher A. "Adalimumab: Another Treatment Option for Moderate-to-Severe UC." Gastroenterology & hepatology vol. 9,5 (2013): 321.
Kornbluth AA. Adalimumab: Another Treatment Option for Moderate-to-Severe UC. Gastroenterol Hepatol (N Y). 2013 May;9(5):321. PMID: 23943670; PMCID: PMC3740811.
Copy Download .nbib Format: NLM
Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care Samples.

medRxiv : the preprint server for health sciences

Lee W, Straube S, Sincic R, Noble JA, Montoy JC, Kornblith AE, Prakash A, Wang R, Bainton R, Kurien P.
PMID: 33300003
medRxiv. 2020 Dec 04; doi: 10.1101/2020.12.02.20242750.

INTRODUCTION: The ongoing SARS-CoV-2 pandemic has spurred the development of numerous point of care (PoC) immunoassays. Assessments of performance of available kits are necessary to determine their clinical utility. Previous studies have mostly performed these assessments in a laboratory...

Cite
Lee W, Straube S, Sincic R, et al. Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care Samples. medRxiv. 2020;doi: 10.1101/2020.12.02.20242750.
Lee, W., Straube, S., Sincic, R., Noble, J. A., Montoy, J. C., Kornblith, A. E., Prakash, A., Wang, R., Bainton, R., & Kurien, P. (2020). Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care Samples. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.12.02.20242750
Lee, Won, et al. "Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care Samples." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.12.02.20242750
Lee W, Straube S, Sincic R, Noble JA, Montoy JC, Kornblith AE, Prakash A, Wang R, Bainton R, Kurien P. Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care Samples. medRxiv. 2020 Dec 04; doi: 10.1101/2020.12.02.20242750. PMID: 33300003; PMCID: PMC7724668.
Copy Download .nbib Format: NLM
Newer Therapies for Inflammatory Bowel Disease.

Current treatment options in gastroenterology

Legnani P, Kornbluth A.
PMID: 15149578
Curr Treat Options Gastroenterol. 2004 Jun;7(3):161-167. doi: 10.1007/s11938-004-0037-x.

Recent controlled and uncontrolled trial data in inflammatory bowel disease have suggested several new avenues of possible therapies and refined our understanding of the uses and selectiveness of anti-tumor necrosis factor (TNF)-based therapies. Infliximab remains the only proven effective...

Cite
Legnani P, Kornbluth A. Newer Therapies for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2004;7(3):161-167doi: 10.1007/s11938-004-0037-x.
Legnani, P., & Kornbluth, A. (2004). Newer Therapies for Inflammatory Bowel Disease. Current treatment options in gastroenterology, 7(3), 161-167. https://doi.org/10.1007/s11938-004-0037-x
Legnani, Peter, and Kornbluth, Asher. "Newer Therapies for Inflammatory Bowel Disease." Current treatment options in gastroenterology vol. 7,3 (2004): 161-167. doi: https://doi.org/10.1007/s11938-004-0037-x
Legnani P, Kornbluth A. Newer Therapies for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2004 Jun;7(3):161-167. doi: 10.1007/s11938-004-0037-x. PMID: 15149578.
Copy Download .nbib Format: NLM
Characterizing the gut microbiome in trauma: significant changes in microbial diversity occur early after severe injury.

Trauma surgery & acute care open

Howard BM, Kornblith LZ, Christie SA, Conroy AS, Nelson MF, Campion EM, Callcut RA, Calfee CS, Lamere BJ, Fadrosh DW, Lynch S, Cohen MJ.
PMID: 29766103
Trauma Surg Acute Care Open. 2017 Oct 23;2(1):e000108. doi: 10.1136/tsaco-2017-000108. eCollection 2017.

BACKGROUND: Recent studies have demonstrated the vital influence of commensal microbial communities on human health. The central role of the gut in the response to injury is well described; however, no prior studies have used culture-independent profiling techniques to...

Cite
Howard BM, Kornblith LZ, Christie SA, et al. Characterizing the gut microbiome in trauma: significant changes in microbial diversity occur early after severe injury. Trauma Surg Acute Care Open. 2017;2(1):e000108doi: 10.1136/tsaco-2017-000108.
Howard, B. M., Kornblith, L. Z., Christie, S. A., Conroy, A. S., Nelson, M. F., Campion, E. M., Callcut, R. A., Calfee, C. S., Lamere, B. J., Fadrosh, D. W., Lynch, S., & Cohen, M. J. (2017). Characterizing the gut microbiome in trauma: significant changes in microbial diversity occur early after severe injury. Trauma surgery & acute care open, 2(1), e000108. https://doi.org/10.1136/tsaco-2017-000108
Howard, Benjamin M, et al. "Characterizing the gut microbiome in trauma: significant changes in microbial diversity occur early after severe injury." Trauma surgery & acute care open vol. 2,1 (2017): e000108. doi: https://doi.org/10.1136/tsaco-2017-000108
Howard BM, Kornblith LZ, Christie SA, Conroy AS, Nelson MF, Campion EM, Callcut RA, Calfee CS, Lamere BJ, Fadrosh DW, Lynch S, Cohen MJ. Characterizing the gut microbiome in trauma: significant changes in microbial diversity occur early after severe injury. Trauma Surg Acute Care Open. 2017 Oct 23;2(1):e000108. doi: 10.1136/tsaco-2017-000108. eCollection 2017. PMID: 29766103; PMCID: PMC5877916.
Copy Download .nbib Format: NLM
Trauma Early Mortality Prediction Tool (TEMPT) for assessing 28-day mortality.

Trauma surgery & acute care open

Kunitake RC, Kornblith LZ, Cohen MJ, Callcut RA.
PMID: 29766125
Trauma Surg Acute Care Open. 2018 Jan 08;3(1):e000131. doi: 10.1136/tsaco-2017-000131. eCollection 2018.

BACKGROUND: Prior mortality prediction models have incorporated severity of anatomic injury quantified by Abbreviated Injury Severity Score (AIS). Using a prospective cohort, a new score independent of AIS was developed using clinical and laboratory markers present on emergency department...

Cite
Kunitake RC, Kornblith LZ, Cohen MJ, et al. Trauma Early Mortality Prediction Tool (TEMPT) for assessing 28-day mortality. Trauma Surg Acute Care Open. 2018;3(1):e000131doi: 10.1136/tsaco-2017-000131.
Kunitake, R. C., Kornblith, L. Z., Cohen, M. J., & Callcut, R. A. (2018). Trauma Early Mortality Prediction Tool (TEMPT) for assessing 28-day mortality. Trauma surgery & acute care open, 3(1), e000131. https://doi.org/10.1136/tsaco-2017-000131
Kunitake, Ryan C, et al. "Trauma Early Mortality Prediction Tool (TEMPT) for assessing 28-day mortality." Trauma surgery & acute care open vol. 3,1 (2018): e000131. doi: https://doi.org/10.1136/tsaco-2017-000131
Kunitake RC, Kornblith LZ, Cohen MJ, Callcut RA. Trauma Early Mortality Prediction Tool (TEMPT) for assessing 28-day mortality. Trauma Surg Acute Care Open. 2018 Jan 08;3(1):e000131. doi: 10.1136/tsaco-2017-000131. eCollection 2018. PMID: 29766125; PMCID: PMC5887834.
Copy Download .nbib Format: NLM
Blunt trauma induced splenic blushes are not created equal.

World journal of emergency surgery : WJES

Burlew CC, Kornblith LZ, Moore EE, Johnson JL, Biffl WL.
PMID: 22462560
World J Emerg Surg. 2012 Mar 30;7:8. doi: 10.1186/1749-7922-7-8.

BACKGROUND: Currently, evidence of contrast extravasation on computed tomography (CT) scan is regarded as an indication for intervention in splenic injuries. In our experience, patients transferred from other institutions for angioembolization have often resolved the blush upon repeat imaging...

Cite
Burlew CC, Kornblith LZ, Moore EE, et al. Blunt trauma induced splenic blushes are not created equal. World J Emerg Surg. 2012;7:8doi: 10.1186/1749-7922-7-8.
Burlew, C. C., Kornblith, L. Z., Moore, E. E., Johnson, J. L., & Biffl, W. L. (2012). Blunt trauma induced splenic blushes are not created equal. World journal of emergency surgery : WJES, 78. https://doi.org/10.1186/1749-7922-7-8
Burlew, Clay Cothren, et al. "Blunt trauma induced splenic blushes are not created equal." World journal of emergency surgery : WJES vol. 7 (2012): 8. doi: https://doi.org/10.1186/1749-7922-7-8
Burlew CC, Kornblith LZ, Moore EE, Johnson JL, Biffl WL. Blunt trauma induced splenic blushes are not created equal. World J Emerg Surg. 2012 Mar 30;7:8. doi: 10.1186/1749-7922-7-8. PMID: 22462560; PMCID: PMC3337796.
Copy Download .nbib Format: NLM
Cyclosporine versus infliximab for the treatment of severe ulcerative colitis.

Gastroenterology & hepatology

Kornbluth A.
PMID: 22298961
Gastroenterol Hepatol (N Y). 2011 Oct;7(10):677-9.

No abstract available.

Cite
Kornbluth A. Cyclosporine versus infliximab for the treatment of severe ulcerative colitis. Gastroenterol Hepatol (N Y). 2011;7(10):677-9
Kornbluth, A. (2011). Cyclosporine versus infliximab for the treatment of severe ulcerative colitis. Gastroenterology & hepatology, 7(10), 677-9.
Kornbluth, Asher. "Cyclosporine versus infliximab for the treatment of severe ulcerative colitis." Gastroenterology & hepatology vol. 7,10 (2011): 677-9.
Kornbluth A. Cyclosporine versus infliximab for the treatment of severe ulcerative colitis. Gastroenterol Hepatol (N Y). 2011 Oct;7(10):677-9. PMID: 22298961; PMCID: PMC3265010.
Copy Download .nbib Format: NLM
Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.

Gastroenterology & hepatology

Ha C, Kornbluth A.
PMID: 27524947
Gastroenterol Hepatol (N Y). 2014 Dec;10(12):793-800.

The management of Crohn's disease and ulcerative colitis has become increasingly complex. With the current utilization of immunosuppressive therapies earlier in the disease course for patients presenting with moderate to severe disease, there is a great need for additional...

Cite
Ha C, Kornbluth A. Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2014;10(12):793-800
Ha, C., & Kornbluth, A. (2014). Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. Gastroenterology & hepatology, 10(12), 793-800.
Ha, Christina, and Kornbluth, Asher. "Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis." Gastroenterology & hepatology vol. 10,12 (2014): 793-800.
Ha C, Kornbluth A. Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2014 Dec;10(12):793-800. PMID: 27524947; PMCID: PMC4980813.
Copy Download .nbib Format: NLM
Evaluating a Web-based Point-of-care Ultrasound Curriculum for the Diagnosis of Intussusception.

AEM education and training

Lin-Martore M, Olvera MP, Kornblith AE, Zapala M, Addo N, Lin M, Werner HC.
PMID: 34041433
AEM Educ Train. 2020 Sep 23;5(3):e10526. doi: 10.1002/aet2.10526. eCollection 2021 Jul.

OBJECTIVES: Intussusception is a pediatric medical emergency that can be difficult to diagnose. Radiology-performed ultrasound is the diagnostic study of choice but may lead to delays due to lack of availability. Point-of-care ultrasound for intussusception (POCUS-I) studies have shown...

Cite
Lin-Martore M, Olvera MP, Kornblith AE, et al. Evaluating a Web-based Point-of-care Ultrasound Curriculum for the Diagnosis of Intussusception. AEM Educ Train. 2020;5(3):e10526doi: 10.1002/aet2.10526.
Lin-Martore, M., Olvera, M. P., Kornblith, A. E., Zapala, M., Addo, N., Lin, M., & Werner, H. C. (2021). Evaluating a Web-based Point-of-care Ultrasound Curriculum for the Diagnosis of Intussusception. AEM education and training, 5(3), e10526. https://doi.org/10.1002/aet2.10526
Lin-Martore, Margaret, et al. "Evaluating a Web-based Point-of-care Ultrasound Curriculum for the Diagnosis of Intussusception." AEM education and training vol. 5,3 (2021): e10526. doi: https://doi.org/10.1002/aet2.10526
Lin-Martore M, Olvera MP, Kornblith AE, Zapala M, Addo N, Lin M, Werner HC. Evaluating a Web-based Point-of-care Ultrasound Curriculum for the Diagnosis of Intussusception. AEM Educ Train. 2020 Sep 23;5(3):e10526. doi: 10.1002/aet2.10526. eCollection 2021 Jul. PMID: 34041433; PMCID: PMC8138103.
Copy Download .nbib Format: NLM
Challenging Traditional Paradigms in Posttraumatic Pulmonary Thromboembolism.

JAMA surgery

Knudson MM, Moore EE, Kornblith LZ, Shui AM, Brakenridge S, Bruns BR, Cipolle MD, Costantini TW, Crookes BA, Haut ER, Kerwin AJ, Kiraly LN, Knowlton LM, Martin MJ, McNutt MK, Milia DJ, Mohr A, Nirula R, Rogers FB, Scalea TM, Sixta SL, Spain DA, Wade CE, Velmahos GC.
PMID: 34910098
JAMA Surg. 2021 Dec 15;e216356. doi: 10.1001/jamasurg.2021.6356. Epub 2021 Dec 15.

IMPORTANCE: Pulmonary clots are seen frequently on chest computed tomography performed after trauma, but recent studies suggest that pulmonary thrombosis (PT) and pulmonary embolism (PE) after trauma are independent clinical events.OBJECTIVE: To assess whether posttraumatic PT represents a distinct...

Cite
Knudson MM, Moore EE, Kornblith LZ, et al. Challenging Traditional Paradigms in Posttraumatic Pulmonary Thromboembolism. JAMA Surg. 2021;e216356doi: 10.1001/jamasurg.2021.6356.
Knudson, M. M., Moore, E. E., Kornblith, L. Z., Shui, A. M., Brakenridge, S., Bruns, B. R., Cipolle, M. D., Costantini, T. W., Crookes, B. A., Haut, E. R., Kerwin, A. J., Kiraly, L. N., Knowlton, L. M., Martin, M. J., McNutt, M. K., Milia, D. J., Mohr, A., Nirula, R., Rogers, F. B., Scalea, T. M., Sixta, S. L., Spain, D. A., Wade, C. E., & Velmahos, G. C. (2021). Challenging Traditional Paradigms in Posttraumatic Pulmonary Thromboembolism. JAMA surgery, e216356. https://doi.org/10.1001/jamasurg.2021.6356
Knudson, M Margaret, et al. "Challenging Traditional Paradigms in Posttraumatic Pulmonary Thromboembolism." JAMA surgery vol. (2021): e216356. doi: https://doi.org/10.1001/jamasurg.2021.6356
Knudson MM, Moore EE, Kornblith LZ, Shui AM, Brakenridge S, Bruns BR, Cipolle MD, Costantini TW, Crookes BA, Haut ER, Kerwin AJ, Kiraly LN, Knowlton LM, Martin MJ, McNutt MK, Milia DJ, Mohr A, Nirula R, Rogers FB, Scalea TM, Sixta SL, Spain DA, Wade CE, Velmahos GC. Challenging Traditional Paradigms in Posttraumatic Pulmonary Thromboembolism. JAMA Surg. 2021 Dec 15;e216356. doi: 10.1001/jamasurg.2021.6356. Epub 2021 Dec 15. PMID: 34910098.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries